Ben Ouyang

Ben Ouyang

Auto-generated profile, based on publicly available information

Ben Ouyang

Massachusetts General Hospital 3 Mass General Brigham Cancer Center Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Nature Materials
Verified
Journal Article
Closed access
PDF file
SSShrey Sindhwani
Shrey Sindhwani
Muhammad Ali SyedMuhammad Ali Syed
Muhammad Ali Syed
JNJessica Ngai
Jessica Ngai
BKBenjamin R. Kingston
Benjamin R. Kingston
LMLaura Maiorino
Laura Maiorino
WCWarren C. W. Chan
Warren C. W. Chan

10 August 2020 in Nature Materials
Verified
Journal Article
Closed access
PDF file
BOBen Ouyang
Ben Ouyang
WPWilson Poon
Wilson Poon
YZYi-Nan Zhang
Yi-Nan Zhang
ZLZachary P. Lin
Zachary P. Lin
BKBenjamin R. Kingston
Benjamin R. Kingston
WCWarren C. W. Chan
Warren C. W. Chan

7 September 2020 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
WPWilson Poon
Wilson Poon
BKBenjamin R. Kingston
Benjamin R. Kingston
BOBen Ouyang
Ben Ouyang
WNWayne Ngo
Wayne Ngo
WCWarren C. W. Chan
Warren C. W. Chan

1 June 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
DGDylan Glancy
Dylan Glancy
YZYuwei Zhang
Yuwei Zhang
JWJamie L.Y. Wu
Jamie L.Y. Wu
BOBen Ouyang
Ben Ouyang
SOSeiichi Ohta
Seiichi Ohta
WCWarren C.W. Chan
Warren C.W. Chan

1 February 2026 in Cancer Research Communications
Verified
Journal Article
Open access
NPNussara Pakvisal
Nussara Pakvisal
LPLeontios Pappas
Leontios Pappas
BCBennett A. Caughey
Bennett A. Caughey
NHNora K. Horick
Nora K. Horick
NTNoelia Tarazona
Noelia Tarazona
APAparna Parikh
Aparna Parikh
Immune checkpoint inhibitors (ICI) have limited efficacy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), potentially because of immunosuppressive mechanisms associated with liver metastases. The impact of liver metastases on survival outcomes was evaluated in a retrospective cohort of patients with MSS mCRC treated with ICI-based therapies at Mass General Brigham between January 2015 and December 2022. Patients were stratified by liver metastasis status at ICI initiation. The primary endpoint was progression-free survival (PFS); the secondary endpoint was overall survival (OS). A total of 132 patients were included, of whom 93 (70.5%) had liver metastases at ICI initiation. Most patients in both groups had received ≥2 prior lines of therapy. No significant differences were observed between groups for RAS/BRAF mutation status or tumor mutational burden. Patients without liver metastases demonstrated higher clinical benefit rates (46.2% vs. 16.1%; P = 0.001), longer median PFS (2.5 vs. 2.1 months; HR, 1.68; P = 0.009), and higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median OS was also prolonged in patients without liver metastases (11.5 vs. 6.2 months; HR, 2.03; P < 0.001). No history of liver metastases was an independent favorable risk factor for PFS and OS in univariable and multivariable analyses. These findings indicate that liver metastases are associated with inferior survival outcomes in patients with MSS mCRC treated with ICI-based therapies, supporting the immunosuppressive role of liver metastases and underscoring the importance of stratifying patients by liver metastasis status to guide patient selection and optimize therapeutic strategies. Significance: The limited efficacy of ICIs in MSS mCRC remains a major challenge. The association between liver metastases and inferior outcomes supports the liver’s immunosuppressive role and suggests that liver metastasis status may guide patient selection and treatment optimization.

18 February 2026
Verified
Other
Open access
NPNussara Pakvisal
Nussara Pakvisal
LPLeontios Pappas
Leontios Pappas
BCBennett A. Caughey
Bennett A. Caughey
NHNora K. Horick
Nora K. Horick
NTNoelia Tarazona
Noelia Tarazona
APAparna Parikh
Aparna Parikh
Univariable and multivariable Cox regression analysis for OS.